Literature DB >> 2627748

Body composition in acromegaly: the effect of treatment.

B A Bengtsson1, R J Brummer, S Edén, I Bosaeus, G Lindstedt.   

Abstract

Total body water (TBW) and total potassium (TBK) were measured in patients participating in a follow-up investigation of all acromegalic patients seen between 1956 and 1984. The results were compared with population-based estimates of TBK and TBW calculated from height (BH), weight (BW) age and sex, using data from a large number of healthy subjects (n = 476). The findings were compared with values obtained at diagnosis and were also related to growth hormone (GH) and IGF-I/SmC concentrations at follow-up. BW at follow-up was unchanged compared to BW at diagnosis and was 9.7 and 10.0 kg higher in males and females, respectively, than in healthy subjects of the same BH (BWnorm). Growth hormone concentration at follow-up correlated directly with excess extracellular fluid volume (ECW%) (P less than 0.001) and inversely with the ratio observed/predicted body fat (BF%) (P less than 0.001) as well as with BW/BWnorm (P less than 0.05). On the other hand, GH concentration did not correlate with excess body cell mass (BCM%) estimated from TBK. IGF-I/SmC concentration correlated with GH concentration at follow-up (P less than 0.001) and with ECW% (P less than 0.01) but not with BCM% or BF%. In 39 patients, data on body composition were also available at diagnosis. Of these, three males had developed gonadal insufficiency and their BCM had decreased markedly. One patient had suffered from hemiplegia. Five patients had not received any treatment. In the remaining 30 treated patients, those with a post-treatment GH concentration below 5 mU/l were normalized with respect to ECW and BF. BCM, however, was unchanged. In contrast, patients with GH concentration greater than or equal to mU/l displayed unchanged body composition. Furthermore, BH decreased significantly in successfully treated patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2627748     DOI: 10.1111/j.1365-2265.1989.tb01272.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  12 in total

1.  Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature.

Authors:  Claire Briet; Mirela Diana Ilie; Emmanuelle Kuhn; Luigi Maione; Sylvie Brailly-Tabard; Sylvie Salenave; Bertrand Cariou; Philippe Chanson
Journal:  Endocrine       Date:  2018-11-05       Impact factor: 3.633

2.  IGF-1 levels across the spectrum of normal to elevated in acromegaly: relationship to insulin sensitivity, markers of cardiovascular risk and body composition.

Authors:  Tirissa J Reid; Zhezhen Jin; Wei Shen; Carlos M Reyes-Vidal; Jean Carlos Fernandez; Jeffrey N Bruce; Jane Kostadinov; Kalmon D Post; Pamela U Freda
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

3.  Adipose Tissue Redistribution and Ectopic Lipid Deposition in Active Acromegaly and Effects of Surgical Treatment.

Authors:  Carlos M Reyes-Vidal; Hamed Mojahed; Wei Shen; Zhezhen Jin; Fernando Arias-Mendoza; Jean Carlos Fernandez; Dympna Gallagher; Jeffrey N Bruce; Kalmon D Post; Pamela U Freda
Journal:  J Clin Endocrinol Metab       Date:  2015-06-02       Impact factor: 5.958

4.  Increased fibrosis: A novel means by which GH influences white adipose tissue function.

Authors:  Lara A Householder; Ross Comisford; Silvana Duran-Ortiz; Kevin Lee; Katie Troike; Cody Wilson; Adam Jara; Mitchell Harberson; Edward O List; John J Kopchick; Darlene E Berryman
Journal:  Growth Horm IGF Res       Date:  2017-12-20       Impact factor: 2.372

5.  Effects of GH-IGF-I excess and gonadal status on bone mineral density and body composition in patients with acromegaly.

Authors:  M Madeira; L V Neto; G A B de Lima; R O Moreira; L M C de Mendonça; M R Gadelha; M L F Farias
Journal:  Osteoporos Int       Date:  2010-03-20       Impact factor: 4.507

6.  Elevated GH/IGF-I, due to somatotrope-specific loss of both IGF-I and insulin receptors, alters glucose homeostasis and insulin sensitivity in a diet-dependent manner.

Authors:  Manuel D Gahete; José Córdoba-Chacón; Chike V Anadumaka; Qing Lin; Jens C Brüning; C Ronald Kahn; Raúl M Luque; Rhonda D Kineman
Journal:  Endocrinology       Date:  2011-10-11       Impact factor: 4.736

7.  Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly.

Authors:  Pamela U Freda; Wei Shen; Steven B Heymsfield; Carlos M Reyes-Vidal; Eliza B Geer; Jeffrey N Bruce; Dympna Gallagher
Journal:  J Clin Endocrinol Metab       Date:  2008-03-18       Impact factor: 5.958

Review 8.  Effect of growth hormone on insulin signaling.

Authors:  Rita Sharma; John J Kopchick; Vishwajeet Puri; Vishva M Sharma
Journal:  Mol Cell Endocrinol       Date:  2020-09-20       Impact factor: 4.102

9.  Morphological and histopathological changes in orofacial structures of experimentally developed acromegaly-like rats: an overview.

Authors:  Masahiro Iikubo; Ikuho Kojima; Maya Sakamoto; Akane Kobayashi; Hidetoshi Ikeda; Takashi Sasano
Journal:  Int J Endocrinol       Date:  2012-02-28       Impact factor: 3.257

Review 10.  Growth Hormone's Effect on Adipose Tissue: Quality versus Quantity.

Authors:  Darlene E Berryman; Edward O List
Journal:  Int J Mol Sci       Date:  2017-07-26       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.